AcelRx will be able to focus its operations and capital on its high-value asset programmes that are in late stages. Credit: Michal Jarmoluk / Pixabay.

AcelRx Pharmaceuticals has announced the sale of its drug DSUVIA (sufentanil sublingual tablet) to Alora Pharmaceuticals. 

With this agreement, AcelRx will be able to take part in the long-term value expected to be created by Alora as they expand the commercialisation of the drug approved by the Food and Drug Administration (FDA).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company will receive a royalty of 15% on commercial sales of DSUVIA along with a 75% royalty on its sales to the Department of Defense.

The Department of Defense (DoD) is the single largest customer of DSUVIA.

AcelRx will lead the relationship for ensuring the expected expansion of sales to the DoD, in return for the royalty on net sales. 

Additionally, the agreement provides AcelRx sales-based milestones of up to $116.5m. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The transaction is expected to conclude by the end of the month.

After closing, during a period of up to six months, AcelRx will provide and get reimbursement for transition services. 

With this divestment, AcelRx will also be able to focus its operations and capital on its high-value asset programmes that are in late stages, with specific prioritisation of Niyad, its lead nafamostat programme.

AcelRx Pharmaceuticals CEO Vince Angotti said: “As stated previously, our goal has been to find a partner for DSUVIA who is better resourced and has the experience to expand the sales of DSUVIA to the hospital and surgery centre markets and to build on our current momentum in the procedural suites. 

“We believe that the divestment of DSUVIA, plus the advancement of both our nafamostat and pre-filled syringe portfolio programmes, build long-term value for our shareholders and sets us on the path to a new era for the company with multiple late-stage, and potentially commercial-stage assets within the next 12 months.”

Alora is expected to continue to build on AcelRx’s earlier focus on procedural suites by employing the existing sales representatives of AcelRx at closing.

DSUVIA is indicated to be used in adults to manage acute pain severe enough to require an opioid analgesic.